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ABSTRACT 
The present study was carried out to formulate and evaluate multiparticulate system 
containing mini-tablets of Naproxen sodium. Naproxen is a nonsteroidal anti-inflammatory 
drug (NSAIDs) with analgesic and antipyretic properties. Pre-formulation studies showed 
good ﬂow and compaction capacity, leading to the production of highquality mini-tablets. 
The drug-excipients compatibility studies were performed using FTIR techniques. Ten 
different matrix mini tablets were manufactured by direct compression using various 
polymers like HPMC K4M, PVP K30 in different ratio. The prepared mini tablets were 
subjected to pre and post compressional parameters and the values were within the prescribed 
limits. The in-vitro performance showed the desired biphasic behaviour. Drug release from 
matrix mini tablets was sustained over a period of 10 hours and release rate. Study concludes 
that Naproxen sodium can be successfully released in a controlled manner by the use of 
developed matrix mini-tablets. 
Keywords: in-vitro study mini tablets, , NSAIDs, HPMC K4M, PVP K30, Naproxen 
sodium. 
 
INTRODUCTION 
Oral tablets are the mostwidely used dosage form due to compactness, ease in manufacturing 
and convenience in terms of self-administration
1
.   
Matrix technologies are very popular among the oral controlled drug delivery technologies 
due to their simplicity, ease in manufacturing, high level of reproducibility, stability of the 
raw materials and dosage form and ease of scale-up and process validation
2,3,4
. Matrix tablets 
are the “oral solid dosage forms in which the drug or active ingredient is homogeneously 
dispersed throughout the hydrophilic or hydrophobic matrices which serves as release rate 
retardants. Mini tablets are yet another category ofsolid oral formulation that offers analogous 
therapeutic benefits. Mini tablets have diameter typically equal to or smaller than 3.0 mm
5,6
. 
Mini tablets can be prepared very easily by the means of direct compression method. These 
mini tablets can be filled into hard gelatine capsules, can be administered with a dose 
dispenser for individual dosing or can be compressed into larger tablets
7,8
.  
Matrix mini tablets as multiparticulate dosage forms score more advantages like uniformity 
of drug release, less tendency of dose dumping, greater patience compliance, improved 
mechanical strength, more dose loading capacity, and uniformity of size and shape
9
. 
Furthermore minitablets can maintain their structure and shape in a more reproducible way 
than pellets or granules
10
.  
The significant anatomical differences of the buccalcavity within paediatric and adult patients 
mean that children, particularly those under 5 years of age, encounter swallowing difficulties. 
Mini tablets are a potentially suitable dosage form for paediatric drug delivery
11,12
. 
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic 
properties that relieves pain, fever, swelling, and stiffness. It is commonly used as sodium 
salt
13
. Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo 
bioavailability of 95%. Naproxen is extensively metabolized to 6-0-desmethyl naproxen and 
both parent and metabolites do not induce metabolizing enzymes
14
,
15
.  
The aim of present investigation is to design development and characterize the controlled 
release matrix mini tablets of Naproxen sodium with varying proportionsof selective 
polymers. To release the drug for a prolong period of time within the GIT, thus to improve 
the patient compliance. By the means of controlled drug delivery systems danger of dose 
dumping and alteration in drug release profile can be avoided. 
  
MATERIALS AND METHODS 
Materials 
 
Naproxen sodium was obtained from Adpharm Pharmaceuticals Limited, Lagos State, 
Nigeria. PVP K30 and Magnesium stearate were obtained from Afrab-Chem Limited, Lagos 
State, Nigeria. Aerosil was obtained from Agary Pharmaceutical Limited, Lagos State, 
Nigeria. Sodium lauryl Sulphate and Avicel were obtained from Biopharma Nigeria Limited, 
Lagos State, Nigeria. All other ingredients, chemicals and solvents used were of analytical 
grade. 
 
PREFORMULATION STUDIES 
Fourier Transform Infrared (FTIR) spectral analysis 
 
The compatibility for pure drug Naproxen, polymers andtheir physical mixtures used in this 
experimental procedure was evaluated by recording of spectra using FT-IR 
Spectrophotometer (Perkin Elmer, spectrum-100, Japan). The spectra were recorded by 
taking 5% of sample in potassium bromide (KBr) and after this mixture was grounded into a 
fine powder it was compressed into KBr pellets at 4000 Psi 
compaction pressure for a period of 2 min. The resolution was 1 cm1 and the range of 
scanning was 400–4000 cm-1 
 
Angle of repose 
The fixed funnel and free standing cone methods employ a funnel that is secured with its tip 
at a given height, h, which was kept 2 cm above graph paper that is placed on a flat horizontal 
surface. With r being the radius, of base of conical pile, angle of repose can be determined by 
following equation: 
= tan-1 (h/r) 
Where,  is the angle of repose, h is height of pile, r is radius of base of the pile. 
Bulk density and tapped density 
Both loose bulk density and tapped bulk density were determined.A quantity of 2gm of 
granules from each formula, previously light Shaken for the break of any agglomerates 
formed, was introduced into the 10ml of measuring cylinder. After the initial volume was 
observed, the cylinder was allowed to fall down its own weight from the hard surface from a 
height of 2.5cm at 2 sec Intervals. The tapping was continued until no further change in the 
volume was noted LBD and TBD were calculated using the following formulas: 
Bulk Density=(Weight of sample (gm))/(Volume occupied by sample (ml)) 
 
Bulk Density=(Weight of powdered blend (gm))/(Tapped volume of the packing (ml)) 
Compressibility index 
The compressibility index of the granules was determined by Carr’s Compressibility index. 
Compressibility Index=(Tapped Density-Bulk Density)/(Tapped Density) X100 
Hausner’s ratio 
Hausner’s ratio can be determined by the following equation, 
Hausner Ratio=(Tapped Density)/(Bulk Density) 
 
Preparation of matrix mini tablet 
Naproxen sodium matrix mini-tablets were prepared by directcompression technique. Tablet 
ingredients were accurately weighed as mentioned in the table 1. All ingredients were then 
passed through #20 mesh sieve. After screening, the powdered ingredients were blended in a 
 large size poly bag by tumbling action. Finally, magnesium stearate was added and again 
mixed for 5 minutes so that particle surface was coated by lubricant evenly. The blend was 
then compressed into mini tablets weighing about 100 mg using 2.8 mm shallow biconcave 
punches in rotary tablet punching machine to a hardness of 5-6 kg/cm
2
. The prepared mini 
tablets were used for further evaluation studies. 
Table 1: Composition of Naproxen sodium matrix mini-tablets formulations (mg/mini 
tablet) 
Code  
Drug 
(mg)  
HPMC 
K4M 
(mg)   
PVP 
K30 
(mg) 
Magnesium 
stearate 
(mg) 
Aerosil 
(mg) 
 
Sodium 
lauryl 
Sulphate 
(mg) 
Avicel 
(mg) 
 
MT1  18 1.20 1 0.25 0.25 0.20 10.10 
MT2 18 1.26 1 0.25 0.25 0.20 11.24 
MT3 18 2.42 1 0.25 0.25 0.20 12.58 
MT4 18 2.68 1 0.25 0.25 0.20 14.32 
MT5 18 2.70 1 0.25 0.25 0.20 15.60 
MT6 18 3.10 1 0.25 0.25 0.20 16.20 
MT7 18 3.42 1 0.25 0.25 0.20 15.88 
MT8 18 3.52 1 0.25 0.25 0.20 16.78 
MT9 18 3.68 1 0.25 0.25 0.20 15.62 
MT10 18 3.79 1 0.25 0.25 0.20 15.51 
 
 
EVALUATION OF NAPROXEN SODIUM MATRIX MINI TABLET  
Tablet thickness 
The thickness of 20 Naproxen sodium matrix mini-tablets was determined using a Vernier 
caliper and the mean of these readings was taken as the mean tablet thickness. 
Tablet weight uniformity 
Ten Naproxen sodium matrix mini-tablets were weighedindividually on electric balance from 
which the mean was calculated and the percentage deviations determined. 
Friability 
A friability test was conducted on the tablets using an veego friabilator. Twenty Naproxen 
sodium matrix mini-tablets were selected from each batch and any loose dust was removed 
with the help of a soft brush. The tablets were initially weighed (Wi) and transferred into 
friabilator. The drum was rotated at 25 rpm for 4 minutes after which the tablets were 
removed. Any loose dust was removed from the tablets as before and the tablets were 
weighed again (Wf). The friability of tablets less than 1% is considered acceptable. The 
percentage friability was then calculated by, 
%F=(Wi-Wf)/Wi X100 
 
Hardness 
The Naproxen sodium matrix mini-tablets to be tested were held between a fixed and a 
moving jaw of hardness test apparatus (Monsanto) and reading of the indicator is adjusted to 
zero. The screw knob was moved forward until the tablet breaks and the force required 
breaking the tablet was noted. 
Drug content 
The drug content in each Naproxen sodium matrix mini-tablet was determined by triturating 
20 tablets and powder equivalent to average weight was added in 100 ml pH 1.2 HCL, 7.4 
and 6.8 pH phosphate buffer, followed by stirring. The solution was filtered through a 0.45μ 
membrane filter, diluted suitably and the absorbance of resultant solution was measured 
spectrophotometrically at 331 nm using pH 1.2 HCL and pH 7.4, 6.8 phosphatembuffers as 
blank.  
 In-vitro drug release study 
In vitro release studies of Naproxen sodium matrix mini-tablets were carried out using a 
modified USP XXIII dissolution test apparatus. The dissolution study was conducted for all 
the formulations using paddle method. The dissolution test was performed using 900ml of 
buffer pH 7.4 at a speed of 50 rpm and the temperature of 37
o
C was used in each test samples 
of dissolution(5ml) were withdrawn and absorbance was measured at 331 nm using analysis 
by UV spectroscopy. The dissolution data was fitted tomodels such as zero-order, first-order, 
Higuchi and Peppa’s –Korsemeyer equations.  
 
 
 
Figure 1: FTIR spectrum of Naproxen sodium 
The FT-IR studies showed that C-H stretching, C-O stretching, C-H bending, O-H 
deformation, C-H out of plane bending of pure Naproxen sodium and with  PVP K30 and 
HPMC K4M were almost in the same region of wave number ranging from 4000 cm
-1 to 400 
cm
-1
. It showed that there was no significant interaction betweenthe drug and polymer and 
they are compatible with each other. 
 
Figure 2: FTIR spectrum of mixture of Naproxen sodium, PVP K30 and HPMC K4M. 
 
 
  
 
 
 
Table 2: Results of physical evaluation of Pre-compression Blend 
Code 
 
 
 
Angle of 
repose (°) 
mean± SD, 
n=3 
Bulk density 
(g/cc) 
mean± SD, 
n=3 
Tapped 
density (g/cc) 
mean± SD, 
n=3 
Carr’s index 
(%) 
mean± SD, 
n=3 
Hausner’s ratio 
mean± SD, n=3 
 
 
MT1  24.59±0.09 0.521 ± 0.32 0.581 ± 0.09  10.32± 0.22  1.11±0.08 
MT2  22.31±0.35 0.558 ± 0.09  0.618 ± 0.14  9.70± 0.45  1.10±0.11 
MT3  23.48±0.44 0.547 ± 0.15  0.607± 0.23 9.88± 0.10  1.10±0.24 
MT4  23.75±0.37  0.568 ± 0.38 0.628 ± 0.31  9.55± 0.25  1.10±0.31 
MT5  22.67±0.59  0.564 ± 0.49  0.624 ± 0.08  9.93± 0.47  1.10±0.52 
MT6  21.88±0.82 0.572 ± 0.31 0.632± 0.25 9.49± 0.94  1.10±0.16 
MT7  22.69±0.08  0.548 ± 0.61 0.608 ± 0.09  9.86± 0.62  1.10±0.26 
MT8  22.42±0.07 0.559 ± 0.25  0.619± 0.18 9.69± 0.23  1.10±0.08 
MT9 24.38±0.49 0.572 ± 0.16  0.632 ± 0.06  9.49± 0.17  1.10±0.41 
MT10 22.58±0.39  0.545 ± 0.27  0.605 ± 0.09  11.00± 0.20  1.11±0.09 
 
 
Table 3: Results of physicochemical parameters of all formulations    
Code 
 
 
 
 
Thickness    
(mm), 
(mean±SD), 
n=20 
 
Hardness (kg) 
(mean±SD), 
n=6 
 
 
% Friability 
(mean±SD), 
n=20 
 
 
Weight 
variation, 
(mg) 
(mean±SD), 
n=10 
% Drug 
content 
(mean±SD), 
n=5 
 
MT1  3.7±0.08  4.9 ±0.14 0.45±0.09 305.55±0.09  98.46±0.09 
MT2  4.2±0.15 4.6±0.09 0.38±0.35  303.38±0.06  99.12±0.09 
MT3  3.8±0.38 4.8±0.06 0.43±0.27 300.27±0.11  99.41±0.27 
MT4  3.9±0.05  4.9±0.05 0.39±0.49  298.34±0.43 99.12±0.09 
MT5  4.2±0.62 5.0±0.14  0.35±0.51  299.47±0.51 98.49±0.09 
MT6  4.3±0.41 5.1±0.26 0.40±0.08 304.38±0.60 97.83±0.09 
MT7  4.0±0.53 4.6±0.42 0.42±0.26  303.53±0.23  98.56±0.17 
MT8  4.4±0.08 5.0±0.38 0.38±0.07  307.58±0.58 99.43±0.13 
MT9 3.8±0.12 4.9±0.08 0.45±0.11 303.48±0.93 97.56±0.05 
MT10 4.1±0.36 5.3±0.03 0.41±0.16 305.36±0.41 98.86±0.17 
 
  
Figure 3: In-vitro drug release profile of Naproxen sodium matrix mini-tablets of batch 
MT1 to MT5 
 
 
 
Figure 4: In-vitro drug release profile of Naproxen sodium matrix mini-tablets of batch 
MT6 to MT10 
 
Table 5: Drug release kinetics of different Naproxen sodium matrix mini-tablets 
Formulation 
code 
Zero 
order 
(R
2
) 
 
First 
order (R
2
) 
 
 
Higuchi’s 
(R
2
) 
 
 
Korsemeyer-
Peppa’s (R2) 
R
2
 
 
n 
MT1  0.8815 0.8952 0.7685 0.9356 0.6842 
MT2  0.9239 0.9039 0.8378 0.9238 0.6937 
MT3  0.8641 0.8478 0.7153 0.9129 0.6689 
MT4  0.9049 0.8816 0.7579 0.9348 0.6594 
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Time ( Hrs) 
MT6 
MT7 
MT8 
MT9 
MT10 
 MT5  0.8932 0.9173 0.7368 0.9068 0.6736 
MT6  0.9278 0.8792 0.7932 0.9241 0.6542 
MT7  0.8664 0.8785 0.8649 0.8937 0.6713 
MT8  0.9093 0.9129 0.7583 0.9537 0.6849 
MT9 0.8881 0.9063 0.8594 0.9248 0.6932 
MT10 0.9134 0.9171 0.8951 0.8639 0.6852 
R
2
=Correlation coefficient value, n=slope 
 
The release rate kinetic data for all formulations is shown inTable 5. When the data were 
plotted according to zero order, the formulations showed a high linearity with regression 
coefficient values (R
2
) between 0.8664–0.9278. It showed that the drug release follows zero 
order.  
When the data were plotted according to first order, the formulations showed regression 
coefficient values (R
2
) between 0.8478–0.9173.  Diffusion is related to transport of drug from 
the matrix tablets into the dissolution medium depends upon the concentration.  
This is explained by Higuchi’s equation. When the data were plotted according to Higuchi’s 
equations, the regression co-efficient values (R
2
) were between 0.7153– 0.8951. By using 
Korsmeyer-Peppas model, the mechanism of drug release was determined. If n = < 0.45, it is 
Fickian diffusion and if n= 0.45 – 0.89, it is non Fickian diffusion transport12. The results of 
all the formulations showed that the n values are between 0.6542–0.6937. It proved that all 
formulations followed non-Fickian transport mechanism19 bothdiffusion and erosion9. 
 
RESULTS AND DISCUSSION 
The granules of all the formulations were evaluated for angle of repose, bulk density, 
tapped density, compressibility index and Hausner ratio.  
The angle of repose was found to be in the range of 21.88 to 24.59
o
. It indicates that granules 
have a good flow property. 
The bulk density and tapped density was found to be in the range of 0.521 ± 0.32 to 0.572 ± 
0.31 g/cm
3
 and 0.581 ± 0.09 to 0.633± 0.25 g/cm
3 
respectively. 
The compressibility and Hausner ratio was found to be 9.47± 0.17 to 11.00± 0.20 and 
1.10±0.16 to 1.11±0.09 indicating good flow characterof the granules (table 2). All the results 
are within the prescribed limits. 
The hardness of the tablets for all the formulations was in the range of 5-7 kg/cm2. The 
uniformity weight of twenty tablets of all the formulations was within 5% deviation. The 
friability of all the formulation was less than 1%. Drug content of all the formulations were 
found to be in the range of 96 to 99 % (table 3). All the results are within the prescribed 
limits. 
The FT-IR studies showed that the ingredients are compatible with the Naproxen sodium. 
The results of the in-vitro release study for all the 10 formulations are shown in Figure 3 and 
Figure 4. 
At the end of 10 hrs the maximum cumulative percentage drug release 84.725% was shown 
by the batch MT1 and minimum 55.42 was shown by batch MT8. 
 
 
An increase in the compression force increases the hardness and the apparent density of the 
tablet, thereby reducing the matrix porosity in the tablet. As the compression force increases, 
release rate decreases
6
. The drug release was found to be faster at lower compression force 
than at higher ones because of the relatively larger matrix porosity of the tablet, which 
allowed greater penetration of dissolution fluid into the matrix, thus enhancing polymer 
disentanglement and drug dissolution
11
. The controlled drug release may also be due to 
increased proportion of polymer
15
. 
  
CONCLUSION 
The study was undertaken with the aim to formulation and evaluation of Naproxen sodium 
sustained-release matrix tablets using various concentrations of polymers. It was concluded 
that there was no interaction between the drug and polymer compatibility, which is analyzed 
by FTIR.Ten different formulations of matrix mini tablets were prepared successfully. The 
physicochemical evaluation studies like thickness, hardness, drug content, weight variation 
and friability were performed. From the obtained results, it is concluded that the formulation 
of sustained release tablet of Naproxen sodium of batch MT1is considered as ideal or 
optimized 
Therefore the study proves that Naproxen sodium can be successfully released in a controlled 
manner by the use of developed matrix mini-tablets. 
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